Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim matches the label’s explicit “DO NOT INTERCHANGE” instruction and the stated bioavailability/PK rationale comparing MYKROX to ZAROXOLYN and other metolazone formulations.
Category Scores
Accurate Statements
MYKROX tablets are not therapeutically equivalent/interchangeable with ZAROXOLYN or other metolazone formulations with slow and incomplete bioavailability; formulations bioequivalent to MYKROX should not be interchanged with those bioequivalent to ZAROXOLYN.
Label Section 5 (PRECAUTIONS): “DO NOT INTERCHANGE... MYKROX TABLETS ARE A RAPIDLY AVAILABLE FORMULATION... NOT THERAPEUTICALLY EQUIVALENT TO ZAROXOLYN... OTHER FORMULATIONS... SHARE ITS SLOW AND INCOMPLETE BIOAVAILABILITY... FORMULATIONS BIOEQUIVALENT TO MYKROX AND... BIOEQUIVALENT TO ZAROXOLYN SHOULD NOT BE INTERCHANGED FOR ONE ANOTHER.”
The non-interchangeability rationale is based on differing bioavailability/PK (MYKROX rapid/complete vs others slow/incomplete).
Label Section 5 (PRECAUTIONS) provides the rapid/complete vs slow/incomplete bioavailability rationale; Label Section 12 (CLINICAL PHARMACOLOGY) states other formulations have peak ~8 hours with continued absorption for an additional 12 hours.
Substitution between MYKROX and other metolazone dosage forms requires dose titration (when substituting).
Label Section 2 (DOSAGE AND ADMINISTRATION): “The same dose titration is necessary if MYKROX Tablets are to be substituted for other dosage forms of metolazone...”
Unsupported Statements
Contradictions
Important Omissions
The AI claim did not explicitly include the label’s statement that formulations shown bioequivalent to MYKROX should not be interchanged with formulations bioequivalent to ZAROXOLYN (the label’s bioequivalence pairing nuance).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim tracks the label’s explicit interchange warning, reducing risk of inappropriate substitution based on differing bioavailability/PK.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
Optionally mirror the label’s specific phrasing about not interchanging formulations that are bioequivalent to MYKROX versus those bioequivalent to ZAROXOLYN.